🇺🇸 FDA
Pipeline program

RoActemra 20 mg/mL concentrate for solution for infusion, Glofitamab

GO43075

Phase 2 small_molecule active

Quick answer

RoActemra 20 mg/mL concentrate for solution for infusion, Glofitamab for Diffuse Large B-Cell Lymphoma is a Phase 2 program (small_molecule) at Roche Registration Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Roche Registration Limited
Indication
Diffuse Large B-Cell Lymphoma
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials